The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

Sanofi's (SNY) plans to seperate its consumer care unit draws buyout bids with over €10B in funding committed from banks and ...

Clayton Dubilier & Rice made it a condition for banks to commit more than €1 billion ($1.1 billion) of debt to fund a part of ...

Banks and other lenders are lining up more than €10 billion ($11.1 billion) of debt to back a buyout of Sanofi SA’s consumer ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...